肿瘤药-基因检测-销售代表-上海
广州燃石医学检验所有限公司
- 公司规模：1000-5000人
- 公司性质：民营公司
- 公司行业：制药/生物工程
职位信息
- 发布日期：2019-10-14
- 工作地点：上海
- 招聘人数：3人
- 工作经验：1年经验
- 学历要求：大专
- 职位月薪：0.8-1万/月
- 职位类别：医药学术推广 医药代表
职位描述
工作职责：
*负责NGS二代基因测序（肿瘤诊疗领域)；
* 负责核心三甲医院的销售代表；
* 工作地：上海；
您将收获：
* 只要愿意学，这里有医药最具前景领域前沿技术；
* 只要想发展，这里能开拓未来发展视野，有快速成长的职业通道；
* 团结、共赢的团队氛围；
* TOP SALES优秀销售新星的期权奖励；
* TOP SALES优秀销售团队的海外旅游奖励；
* 海外年会激励；
任职要求：
* 勤奋努力；
* 有较强的学习能力，沟通能力，思路清晰；
* 形象气质佳；
* 大专以上学历，分子生物领域相关专业优先考虑；
* 有1~2年行业销售经验，有肿瘤销售经验优先；
公司介绍
关于燃石医学
燃石医学（纳斯达克代码：BNR）成立于2014年，公司使命为“用科学守护生命之光”，专注于为肿瘤精准医疗提供具有临床价值的二代基因测序（NGS）。公司业务及研发方向主要覆盖：1）基于NGS的肿瘤患病人群检测，6年间，燃石累计检测样本超过18.5万例，在中国市场份额领跑行业；2）基于NGS的癌症早检，目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局（NMPA）颁发的中国肿瘤NGS检测试剂盒，在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核，以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品，推动肿瘤精准医疗领域的发展。
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
燃石医学（纳斯达克代码：BNR）成立于2014年，公司使命为“用科学守护生命之光”，专注于为肿瘤精准医疗提供具有临床价值的二代基因测序（NGS）。公司业务及研发方向主要覆盖：1）基于NGS的肿瘤患病人群检测，6年间，燃石累计检测样本超过18.5万例，在中国市场份额领跑行业；2）基于NGS的癌症早检，目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局（NMPA）颁发的中国肿瘤NGS检测试剂盒，在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核，以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品，推动肿瘤精准医疗领域的发展。
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
联系方式
- Email：simin.huang@brbiotech.com
- 公司地址：广州国际生物岛星岛环北路5号（燃石医学）
- 电话：17710099363